Vistagen Therapeutics, Inc.
Vistagen Therapeutics, Inc. (VTGN): 8 pipeline candidates · 2 upcoming catalysts · ~11 mo cash runway · 7 clinical trials. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
10.5 months
D/E 0.28
Lead: Phase 3
8 candidates
2 upcoming, next in ~105d
N/A
A transparent, data-derived signal for Vistagen Therapeutics, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$27.5M
Cash
$47.4M
Quarterly Burn
$17.6M
Runway
10.5 mo
Revenue
$303K
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (8 candidates)
| Drug | Phase |
|---|---|
| fasedienol | Phase 3 |
| fasedienol nasal spray - fasedienol | Phase 3 |
| itruvone | Phase 2 |
| ph15 | Phase 2 |
| ph284 | Phase 2 |
| ph80 | Phase 2 |
| ph94b | Phase 3 |
| refisolone | — |
Upcoming Catalysts (2)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
55
Total value held
$7.2M
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 3,148,400 | $1.8M |
| orbimed advisors llc | 3,060,000 | $1.7M |
| adar1 capital management, llc | 751,141 | $429K |
| millennium management llc | 644,404 | $368K |
| two sigma investments, lp | 469,619 | $268K |
| geode capital management, llc | 453,391 | $259K |
| blackrock, inc. | 448,507 | $256K |
| luminus management llc | 396,053 | $226K |
| jane street group, llc | 296,011 | $169K |
| renaissance technologies llc | 291,300 | $166K |
Showing top 10 of 55 institutional holders of Vistagen Therapeutics, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Vistagen Therapeutics, Inc.'s pipeline?
Vistagen Therapeutics, Inc. (VTGN) has 8 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Vistagen Therapeutics, Inc.'s lead drug candidate?
Vistagen Therapeutics, Inc.'s most advanced tracked candidate is fasedienol (Phase 3) for Social Anxiety Disorder; Social Anxiety Disorder (SAD).
What is Vistagen Therapeutics, Inc.'s next catalyst?
Vistagen Therapeutics, Inc.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: US, Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial of Fasedienol " — expected October 1, 2026.
What is Vistagen Therapeutics, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Vistagen Therapeutics, Inc. has approximately 10.5 months of cash runway.
What is Vistagen Therapeutics, Inc.'s market capitalization?
Vistagen Therapeutics, Inc.'s market capitalization is approximately $27.5M.
Get the full picture on Vistagen Therapeutics, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.